GeneDx Holdings Warrant
WGSWW
WGSWW wurde am 21. Juli 2026 von der Börse genommen.
Profil: GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
Mitarbeiter: 1.300
Nachrichten
Für WGSWW liegen uns keine aktuellen Nachrichtenartikel vor.